NCLifeSci Emerging Company and Technology Luncheon and Forum

Tom Adams, Ph.D., chief executive officer and co-founder, Pairwise

Adams has over 25 years of leadership experience heading up biotechnology for global companies. He served most recently as vice president of global biotechnology at Monsanto where he led the team developing a broad range of innovative products. Adams wanted to realize the possibilities of CRISPR and gene editing in plants and co-founded Pairwise to develop this potential in a mission-based environment. Formerly a faculty member at Texas A&M University, he holds a Ph.D. in microbiology and plant science from Michigan State University and a B.S. in botany and plant pathology from Oregon State University. 

Anil Goyal, Ph.D., chief executive officer and board director, IMMvention Therapeutix

Goyal is a serial entrepreneur with 30 years of senior management, board, leadership, company formation, fund raising and deal making experience across the biopharma industry in private and public companies. In 2017, he co-founded IMMvention Tx and led the company to secure a strategic and transformative multi-year collaboration with Novo Nordisk in Jan. 2025.  Prior to IMMvention, as chief operating officer at Ribometrix, he raised their first venture funding. Goyal's biotech experience includes MimiVax, Heat Biologics, Serenex (led exit to Pfizer), Optherion (led exit to Sequenom and Baxter), Qualiber, Ascletis and Millennium Pharmaceuticals (acquired by Takeda). Goyal received his Ph.D. in microbiology and molecular genetics from Rutgers University.                                                           

Tom Greene, Ph.D., senior director of Corteva Catalyst, Corteva Agriscience

Greene leads Corteva Catalyst, Corteva Agriscience's external innovation investment group focused on early-stage disruptive technologies in agricultural R&D. He has over 25 years of experience with Corteva and its predecessors, including leading biotech and genome-edited trait pipelines globally. He has authored numerous patents and publications and actively participates in the agricultural scientific community. Green holds a Ph.D. in plant physiology from Washington State University and extensive scientific training.

Neil Jones, vice president of corporate strategic partnerships, Lindy Biosciences

Jones brings over 20 years’ experience in the pharmaceutical and biotech industry with a career that has spanned the continuum from bench top drug discovery to executive leadership in international business development and marketing strategies. At Lindy Biosciences, he is responsible for building their global drug formulation and delivery platform technology brand, fortifying its industry partnerships and navigating the company’s corporate growth strategy to deliver an innovative technology for patients suffering from chronic diseases. Jones holds a bachelor of science from the University of North Carolina at Chapel Hill. 

Dave Moore, executive vice president, U.S. Operations, Novo Nordisk

Moore has more than 20 years of experience in strategy, commercial, market access, business development and investing from working in both large cap pharmaceutical companies, biotech companies and within private equity. In his current role, he has responsibility for the operations in the United States, Novo Nordisk’s largest sales region. From 2017 to 2019, he was senior vice president of commercial at Novo Nordisk, and he led the company through multiple new product launches, including Ozempic. Moore re-joined Novo Nordisk in 2022, leading the corporate development organization. Outside Novo Nordisk, he has served as an investment partner at Gurnet Point Capital, CEO in the infectious disease business at Roivant Sciences, as well as president and chief commercial officer of Cempra Pharmaceuticals. Moore began his career at Johnson & Johnson where he spent 14 years of increasing responsibility. He holds a degree in biology from Towson University and an MBA from Lehigh University.